MADRID, 9 Feb. (EUROPA PRESS) –
PharmaMar shares fell almost 3% this Friday at the market opening, after having announced Sylentis, a group company, that it has not achieved its primary objective in a phase III clinical trial for the treatment of dry eye associated with Sjögren’s syndrome with tivanisiran.
Specifically, PharmaMar shares fell 2.98%, to 35.20 euros per share, although minutes later they reduced their fall to 1.32%, with their shares trading at 35.8 euros.
As PharmaMar communicated this Friday to the National Securities Market Commission (CNMV), “the primary objective” of the clinical trial for the treatment of dry eye was “to evaluate the efficacy (signs and symptoms) and it has not been achieved.”
The pharmaceutical company has indicated that it was a “randomized, double-blind, placebo-controlled” study in which 40 hospitals in the United States, 8 in Spain and 203 patients participated.
“Sylentis would like to thank the patients, families, hospitals, caregivers and medical teams who have made this trial possible,” concludes the company’s communication to the CNMV.
